{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:57:12Z","timestamp":1790495832562,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this multicenter retrospective cohort study was to characterize the incidence, clinical presentation, timing, severity, and management of oral toxicities (OTs) associated with TROP2-directed (datopotamab deruxtecan and sacituzumab govitecan) and HER2-directed (trastuzumab deruxtecan) antibody-drug conjugates in patients with advanced-stage cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective medical-records review of 207 patients was conducted to characterize antibody\u2013drug conjugate (ADC)-associated OTs. Patients had been treated for advanced-stage cancers treated with TROP2 (sacituzumab govitecan and datopotamab deruxtecan) and HER2-directed ADCs (trastuzumab deruxtecan) at the Sapienza University\u2013Hospital and Miami Cancer Institute between 2024 and 2025. Multivariate logistic regressions were performed to evaluate any correlation between the ADC type and prevalence, type, severity, time of onset, and time to resolution of OTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 47 patients (22.7%) developed OTs, with a median onset time of 7.5\u2009days (range: 1-358). The OT prevalence was similar between TROP2 (n\u2009=\u200927, 23.5%) and HER2-directed (n\u2009=\u200920, 21.7%) ADCs, however, oral mucositis (OM) was more frequent with TROP2-directed ADCs (14.8% vs 5.4%, P\u2009=\u2009.04), whereas xerostomia (10.9% vs 6.1%, P\u2009=\u2009.31) and dysgeusia (9.8% vs 5.2%, P\u2009=\u2009.28) were more common and more severe with HER2-directed ADCs, although not reaching statistical significance. Patients receiving TROP2-directed ADCs had a 3.02-fold higher-risk of developing OM compared to those receiving HER2-directed ADCs (95% CI: 1.07-8.52, P\u2009=\u2009.040). In cases of OM, the trajectory of TROP2-associated OM was more acute than with HER-2-associated OM with earlier onset (P\u2009=\u2009.035) and quicker resolution (P\u2009=\u2009.045). Management of OTs was provided for 29 (14.0%) patients with the majority of them receiving TROP2-directed ADCs (n\u2009=\u200921, 17.3%). With regard to OTs, patients developing OM were associated with a greater need for management (n\u2009=\u200919\/22; P\u2009=\u2009.001), compared to xerostomia (n\u2009=\u20098\/17; P\u2009=\u2009.471) and dysgeusia (n\u2009=\u20092\/15; P\u2009=\u2009.196). Ultimately, ADC dose reduction (DR) was required in 43 patients (20.8%) and was significantly more frequent with TROP2-directed ADCs (26.1% vs 14.1%, P\u2009=\u2009.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TROP2-directed ADCs are associated with a higher-risk of OM (P\u2009=\u2009.040) with earlier onset of toxicities (P\u2009=\u2009.035), and greater DR requirements (P\u2009=\u2009.039). In contrast, HER2-directed ADCs are associated with more prevalent xerostomia and dysgeusia, a higher overall severity, and later onset but potentially longer duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag359","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:23:43Z","timestamp":1789755823000},"source":"Crossref","is-referenced-by-count":0,"title":["Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-3391","authenticated-orcid":false,"given":"Paolo J","family":"Fantozzi","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Sciences, Sapienza University of Rome , Rome, 00187,","place":["Italy"]},{"name":"Department of Head and Neck, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sonis","sequence":"additional","affiliation":[{"name":"Divisions of Oral Medicine and Dentistry, Brigham and Women\u2019s Hospital and the Dana-Farber Cancer Institute , Boston, MA 02115,","place":["United States"]},{"name":"Biomodels, LLC and Primary Endpoint Solutions, LLC , Waltham, MA 02451,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-9893","authenticated-orcid":false,"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[{"name":"Department of Radiological, Pathological and Oncological Sciences, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]},{"name":"Medical Oncology Unit, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4943-5622","authenticated-orcid":false,"given":"Simone","family":"Scagnoli","sequence":"additional","affiliation":[{"name":"Department of Radiological, Pathological and Oncological Sciences, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]},{"name":"Medical Oncology Unit, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-3047","authenticated-orcid":false,"given":"Monica","family":"Verrico","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Radiological, Pathological and Oncological Sciences, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]},{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa , Pisa, 56126,","place":["Italy"]},{"name":"Unit of Medical Oncology, Pisa University Hospital , Pisa, 56126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0416-0292","authenticated-orcid":false,"given":"Maria Vittoria","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Radiological, Pathological and Oncological Sciences, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]},{"name":"Medical Oncology Unit, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"Department of Radiological, Pathological and Oncological Sciences, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]},{"name":"Medical Oncology Unit, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Casagrande","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Sciences, Sapienza University of Rome , Rome, 00187,","place":["Italy"]},{"name":"Department of Head and Neck, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4017-4264","authenticated-orcid":false,"given":"Lucia","family":"Borghetti","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Sciences, Sapienza University of Rome , Rome, 00187,","place":["Italy"]},{"name":"Department of Head and Neck, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tenore","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Sciences, Sapienza University of Rome , Rome, 00187,","place":["Italy"]},{"name":"Department of Head and Neck, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankalp","family":"Das","sequence":"additional","affiliation":[{"name":"T&D-Artificial Intelligence and Machine Learning, Baptist Health South Florida , Miami, FL 33176,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Diaz","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Florida International University College of Medicine , Miami, FL 33176,","place":["United States"]},{"name":"Division of Gynecology Oncology, Miami Cancer Institute, Baptist Health South Florida , Miami, FL 33176,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Romeo","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Sciences, Sapienza University of Rome , Rome, 00187,","place":["Italy"]},{"name":"Department of Head and Neck, Umberto I\/Sapienza University Hospital , Rome, 00187,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[{"name":"Department of Orofacial Sciences, University of California San Francisco , San Francisco, CA 94143,","place":["United States"]},{"name":"Oral Medicine, Oral Oncology and Dentistry, Miami Cancer Institute, Baptist Health South Florida , Miami, FL 33176,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092703014378000_oyag359-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026092703014378000_oyag359-B2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026092703014378000_oyag359-B3","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N Engl J Med"},{"key":"2026092703014378000_oyag359-B4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","article-title":"Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy","volume":"15","author":"Joshi","year":"2024","journal-title":"Discov Oncol"},{"key":"2026092703014378000_oyag359-B5","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2026092703014378000_oyag359-B6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1056\/NEJMp1901103","article-title":"Time to study metastatic-cancer survivorship","volume":"380","author":"Langbaum","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092703014378000_oyag359-B7","doi-asserted-by":"publisher","first-page":"e390094","DOI":"10.1200\/EDBK_390094","article-title":"Rise of antibody-drug conjugates: the present and future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"2026092703014378000_oyag359-B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"2026092703014378000_oyag359-B9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"2026092703014378000_oyag359-B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"2026092703014378000_oyag359-B11","doi-asserted-by":"publisher","first-page":"oyaf031","DOI":"10.1093\/oncolo\/oyaf031","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam","year":"2025","journal-title":"Oncologist"},{"key":"2026092703014378000_oyag359-B12","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026092703014378000_oyag359-B13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.2757","article-title":"Effect of trastuzumab deruxtecan on QT\/QTc interval and pharmacokinetics in HER2-positive or HER2-low metastatic\/unresectable breast cancer","volume":"113","author":"Shimomura","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026092703014378000_oyag359-B14","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092703014378000_oyag359-B15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/oncolo\/oyae088","article-title":"Health-related quality of life with sacituzumab govitecan in HR+\/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial","volume":"29","author":"Rugo","year":"2024","journal-title":"Oncologist"},{"key":"2026092703014378000_oyag359-B16","doi-asserted-by":"publisher","first-page":"TPS251","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS251","article-title":"Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy","volume":"38","author":"Lang","year":"2020","journal-title":"JCO"},{"key":"2026092703014378000_oyag359-B17","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1007\/s00520-021-06177-x","article-title":"Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers","volume":"29","author":"Villa","year":"2021","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2026092703014378000_oyag359-B18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10&lt;2103::AID-CNCR2&gt;3.0.CO;2-0","article-title":"Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy","volume":"85","author":"Sonis","year":"1999","journal-title":"Cancer"},{"key":"2026092703014378000_oyag359-B19","author":"National Cancer Institute (NCI)","year":"2025"},{"key":"2026092703014378000_oyag359-B20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026092703014378000_oyag359-B21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026092703014378000_oyag359-B22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092703014378000_oyag359-B23","doi-asserted-by":"publisher","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026092703014378000_oyag359-B24","doi-asserted-by":"publisher","first-page":"e473916","DOI":"10.1200\/EDBK-25-473916","article-title":"Easy as ABC: managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies","volume":"45","author":"Jain","year":"2025","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"2026092703014378000_oyag359-B25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan Lara","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"2026092703014378000_oyag359-B26","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"2026092703014378000_oyag359-B27","doi-asserted-by":"publisher","first-page":"100784","DOI":"10.1016\/j.oor.2026.100784","article-title":"Rationale for effective interventions to mitigate oral mucositis in patients being treated with TROP-2-directed antibody-drug conjugates with a topoisomerase inhibitor payload","volume":"18","author":"Sonis","year":"2026","journal-title":"Oral Oncol Reports"},{"key":"2026092703014378000_oyag359-B28","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"2026092703014378000_oyag359-B29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jobcr.2020.06.003","article-title":"The expression of cathepsin L in oral lichen planus","volume":"10","author":"Kitkhajornkiat","year":"2020","journal-title":"J Oral Biol Craniofacial Res"},{"key":"2026092703014378000_oyag359-B30","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with\u2009&lt;\u2009em\u2009&gt;\u2009EGFR&lt;\/em&gt;-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026092703014378000_oyag359-B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026092703014378000_oyag359-B32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092703014378000_oyag359-B33","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092703014378000_oyag359-B34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092703014378000_oyag359-B35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1470-2045(24)00128-1","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial","volume":"25","author":"Fehm","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026092703014378000_oyag359-B36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026092703014378000_oyag359-B37","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"2026092703014378000_oyag359-B38","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026092703014378000_oyag359-B39","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.esmoop.2024.103479","article-title":"LBA2 datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable\/metastatic HR+\/HER2\u2013 breast cancer (BC): additional safety analysis from TROPION-Breast01","volume":"9","author":"Jhaveri","year":"2024","journal-title":"ESMO Open"},{"key":"2026092703014378000_oyag359-B40","doi-asserted-by":"publisher","first-page":"LBA8500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8500","article-title":"Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): primary results from the phase 3 EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"JCO"},{"key":"2026092703014378000_oyag359-B41","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026092703014378000_oyag359-B42","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026092703014378000_oyag359-B43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA","year":"2022","journal-title":"N Engl J Med."},{"key":"2026092703014378000_oyag359-B44","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026092703014378000_oyag359-B45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00520-024-08689-8","article-title":"MASCC\/ISOO clinical practice statement: management of oral complications of targeted therapy","volume":"32","author":"Villa","year":"2024","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2026092703014378000_oyag359-B46","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Elad","year":"2020","journal-title":"Cancer"},{"key":"2026092703014378000_oyag359-B47","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00520-025-09805-y","article-title":"US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan","volume":"33","author":"Rugo","year":"2025","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2026092703014378000_oyag359-B48","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026092703014378000_oyag359-B49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.adaj.2025.11.015","article-title":"Oral mucositis secondary to datopotamab deruxtecan for advanced-stage cancer managed with cryotherapy after topical steroid failure: a case series study","volume":"157","author":"Fantozzi","year":"2026","journal-title":"J Am Dent Assoc"},{"key":"2026092703014378000_oyag359-B50","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s00520-025-09795-x","article-title":"Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device","volume":"33","author":"Zuniga","year":"2025","journal-title":"Support Care Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag359\/71299165\/oyag359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag359\/71299165\/oyag359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag359\/71299165\/oyag359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:01:49Z","timestamp":1790492509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag359\/8826348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag359","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag359"}}